United Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
United Therapeutics has a total shareholder equity of $6.1B and total debt of $400.0M, which brings its debt-to-equity ratio to 6.6%. Its total assets and total liabilities are $7.1B and $1.0B respectively. United Therapeutics's EBIT is $1.3B making its interest coverage ratio -8.9. It has cash and short-term investments of $3.3B.
Key information
6.6%
Debt to equity ratio
US$400.00m
Debt
| Interest coverage ratio | -8.9x |
| Cash | US$3.33b |
| Equity | US$6.10b |
| Total liabilities | US$1.02b |
| Total assets | US$7.12b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: U2TH34's short term assets ($4.0B) exceed its short term liabilities ($873.4M).
Long Term Liabilities: U2TH34's short term assets ($4.0B) exceed its long term liabilities ($148.8M).
Debt to Equity History and Analysis
Debt Level: U2TH34 has more cash than its total debt.
Reducing Debt: U2TH34's debt to equity ratio has reduced from 36.8% to 6.6% over the past 5 years.
Debt Coverage: U2TH34's debt is well covered by operating cash flow (284.2%).
Interest Coverage: U2TH34 earns more interest than it pays, so coverage of interest payments is not a concern.